$MBOT News

Last published 6d ago

6d agoMBOTMicrobot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization ExpansionGlobeNewswireHINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that the Canadian Intellectual
2w agoMBOTMicrobot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic SystemGlobeNewswireELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The Company believes the OBLs represent a rapidly growing
2w agoMBOTMicrobot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.GlobeNewswireHINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that key executives and members
3w agoMBOTMicrobot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property PortfolioGlobeNewswireThe Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets. HINGHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Microbot
3mo agoMBOTMicrobot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second QuarterGlobeNewswireRevenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April
3mo agoMBOTMicrobot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual MeetingGlobeNewswireHINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year’s Society of
4mo agoMBOTMicrobot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026GlobeNewswireThe Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the
4mo agoMBOTMicrobot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing LeaderGlobeNewswireHINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA)
4mo agoMBOTMicrobot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic SystemGlobeNewswireHINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative
4mo agoMBOTMicrobot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewswireLeading academic center with multi-hospital and multi-state health system deepens Company’s footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System
4mo agoMBOTMicrobot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient PopulationsGlobeNewswireHINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with
5mo agoMBOTMicrobot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewswireHINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that one of the largest healthcare
5mo agoMBOTMicrobot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewswireHINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has secured its first
5mo agoMBOTMicrobot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic SystemGlobeNewswireIsrael becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale Certificate to
5mo agoMBOTMICROBOT MEDICAL LIVE CONFERENCE CALL AND WEBCAST - MICROBOT MEDICAL INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Microbot Medical Live Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a quest
6mo agoMBOTMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary BercuGlobeNewswireConference call and live webcast to be held Monday, May 18th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated third-party article; Research report also references
6mo agoMBOTMicrobot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026GlobeNewswireRecent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across
6mo agoMBOTMicrobot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial SitesGlobeNewswireCommercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization
6mo agoMBOTMicrobot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)GlobeNewswireCommencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician interest at recent
6mo agoMBOTMicrobot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®GlobeNewswireMembers of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least
7mo agoMBOTMicrobot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireHINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will highlight recent
7mo agoMBOTMicrobot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific MeetingGlobeNewswireHINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has successfully
7mo agoSENS MBOT LIVN CLOVMedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValuePR NewswireEquity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory...
7mo agoMBOTEmory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®'s LIBERTY® Endovascular Robotic SystemGlobeNewswireWorld's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System,
7mo agoMBOTMicrobot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical JournalGlobeNewswireBeing Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to
7mo agoMBOT38TH ANNUAL ROTH CONFERENCE - MICROBOT MEDICAL INCEarnings Call TranscriptsOkay. Thank you for joining us for our 38th Annual Roth Conference. I'm Kyle Bowser, Senior Research Analyst with Roth, covering the medical device sector. I'm excited to be joined by Harrel Godot, CEO and President and
8mo agoMBOTMicrobot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First TimeGlobeNewswireHINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at
8mo agoMBOTMicrobot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing RadiationGlobeNewswireHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association's
8mo agoMBOTMicrobot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical EventGlobeNewswireHINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in
8mo agoMBOTTampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewswireHINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital
8mo agoMBOTMicrobot Medical®'s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation ConferenceGlobeNewswireHINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that Harel Gadot, CEO, President
9mo agoMBOTMicrobot Medical®'s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management ConferenceGlobeNewswireInternational Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY® Continues to Gain Commercial Traction and Exposure as
9mo agoMBOTMicrobot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial AdoptionGlobeNewswireHINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it is attending the Society
10mo agoMBOTMicrobot Medical Continues its 2025 Momentum; Announces Key 2026 MilestonesGlobeNewswireLimited Market Release (LMR) of the LIBERTY® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass.,
11mo agoMBOTMicrobot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic SystemGlobeNewswireHINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a
1y agoMBOTMicrobot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.GlobeNewswireCompany Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership Interest and
1y agoMBOTMicrobot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual MeetingGlobeNewswireFirst U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its Commercial
1y agoMBOTMicrobot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic SystemGlobeNewswireThe Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year HINGHAM,
1y agoMBOTMicrobot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross ProceedsGlobeNewswireHINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT) ("Microbot" or the "Company"), today announced the third and final closing of its previously announced exercise of certain
1y agoMBOTMicrobot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property PortfolioGlobeNewswireCommercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global
1y agoMBOTMiocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic SystemGlobeNewswireHINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief Executive
1y agoMBOTMicrobot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross ProceedsGlobeNewswireHINGHAM, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT) ("Microbot" or the "Company"), today announced the first closing of its previously announced exercise of certain outstanding
1y agoMBOTMicrobot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross ProceedsGlobeNewswireBRAINTREE, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT) ("Microbot" or the "Company"), today announced the entry into definitive agreements for the exercise of certain outstanding
1y agoMBOTREMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor ConferenceGlobeNewswireHINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, today announced that Harel Gadot, CEO,
1y agoMBOTMicrobot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic SystemGlobeNewswireAccelerated Launch Readiness Plans Position Company for Commercialization during Q4 2025 The Company's Initial Addressable Market Includes Approximately 2.5 Million Peripheral Endovascular Procedures in the U.S.
1y agoMBOTMicrobot Medical® Granted U.S. Patent that Significantly Expands Potential Market ApplicationsGlobeNewswireWith the Newly Granted IP, the Company's IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans
1y agoDHAI MBOTDIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of DirectorsGlobeNewswireNORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an
1y agoMBOTMicrobot Medical® Receives Non-Dilutive Grant to Enhance Operational CapabilitiesGlobeNewswireHINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a non-dilutive
1y agoMBOTMicrobot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of SalesGlobeNewswireHINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new
1y agoMBOTMicrobot Medical® Added to the Russell Microcap® IndexGlobeNewswireHINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell